Erratum: E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line (Journal of General Virology, (2018), 99, (631-644), 10.1099/jgv.0.001061);E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line

Journal of General Virology

Volumn 99, Issue 5, 2018, Pages 631-644

  Wechsler, Erin Isaacson ^a   Tugizov, Sharof ^a   Herrera, Rossana ^a   Da Costa, Maria ^a   Palefsky, Joel M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anal cancer; Epidermal growth factor; HPV 16 E5; HPV 16 postive anal cell line; Human Papillomaviruses

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FILAGGRIN; GEFITINIB; PROTEIN E5; PROTEIN E6; PROTEIN E7; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRAL PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E5, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN;

ANUS CANCER; ARTICLE; CARCINOGENESIS; GENE REPLICATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 16-TRANSFORMED CELL LINE; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; TUMOR INVASION; ANTAGONISTS AND INHIBITORS; ANUS TUMOR; BIOLOGICAL MODEL; CELL DIFFERENTIATION; EPITHELIUM CELL; GENE KNOCKDOWN; GENETICS; TRANSFORMED CELL LINE; VIROLOGY;

ANUS NEOPLASMS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINE, TRANSFORMED; EPITHELIAL CELLS; ERBB RECEPTORS; GENE KNOCKDOWN TECHNIQUES; HUMAN PAPILLOMAVIRUS 16; HUMANS; MODELS, BIOLOGICAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING;

EID: 85046448381     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/jgv.0.001084     Document Type: Erratum

References (53)

1. Brickman C, Palefsky JM. Human papillomavirus in the HIVinfected host: epidemiology and pathogenesis in the antiretroviral era. Curr HIV/AIDS Rep 2015;12:6–15.
2. Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012;54:1026–1034.
3. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009;124:2375–2383.
4. Steinau M, Unger ER, Hernandez BY, Goodman MT, Copeland G et al. Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. J Low Genit Tract Dis 2013;17:397–403.
5. Genther SM, Sterling S, Duensing S, Münger K, Sattler C et al. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J Virol 2003;77: 2832–2842.
6. Fehrmann F, Klumpp DJ, Laimins LA. Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. J Virol 2003;77: 2819–2831.
7. Regan JA, Laimins LA. Bap31 is a novel target of the human papillomavirus E5 protein. J Virol 2008;82:10042–10051.
8. Kotnik Halavaty K, Regan J, Mehta K, Laimins L. Human papillomavirus E5 oncoproteins bind the A4 endoplasmic reticulum protein to regulate proliferative ability upon differentiation. Virology 2014;452-453:223–230.
9. Chang JL, Tsao YP, Liu DW, Huang SJ, Lee WH et al. The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix. J Biomed Sci 2001;8:206–213.
10. Cavuslu S, Starkey WG, Kell B, Best JM, Cason J. Detection of human papillomavirus type 16 in microtitre plate based immunoenzymatic assays: use to determine E5 gene expression in cervical carcinomas. Clin Diagn Virol 1996;5:215–218.
11. Shirasawa H, Tomita Y, Kubota K, Kasai T, Sekiya S et al. Transcriptional differences of the human papillomavirus type 16 genome between precancerous lesions and invasive carcinomas. J Virol 1988;62:1022–1027.
12. Um SH, Mundi N, Yoo J, Palma DA, Fung K et al. Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer. J Clin Virol 2014;61:94–100.
13. Sahab Z, Sudarshan SR, Liu X, Zhang Y, Kirilyuk A et al. Quantitative measurement of human papillomavirus type 16 e5 oncoprotein levels in epithelial cell lines by mass spectrometry. J Virol 2012;86:9465–9473.
14. Park JS, Hwang ES, Park SN, Ahn HK, Um SJ et al. Physical status and expression of HPV genes in cervical cancers. Gynecol Oncol 1997;65:121–129.
15. Cullen AP, Reid R, Campion M, Lörincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 1991;65:606–612.
16. Matsukura T, Koi S, Sugase M. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology 1989;172:63–72.
17. Straight SW, Herman B, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J Virol 1995;69:3185–3192.
18. Suprynowicz FA, Krawczyk E, Hebert JD, Sudarshan SR, Simic V et al. The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification. J Virol 2010;84:10619–10629.
19. Zhang B, Srirangam A, Potter DA, Roman A. HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes. Oncogene 2005;24:2585–2588.
20. Schrevel M, Gorter A, Kolkman-Uljee SM, Trimbos JB, Fleuren GJ et al. Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer. Mod Pathol 2011; 24:720–728.
21. Mathur SP, Mathur RS, Young RC. Cervical epidermal growth factor- receptor (EGF-R) and serum insulin-like growth factor II (IGFII) levels are potential markers for cervical cancer. Am J Reprod Immunol 2000;44:222–230.
22. Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C et al. Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol 2011;22:2166–2178.
23. Santini J, Formento JL, Francoual M, Milano G, Schneider M et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991;13:132–139.
24. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666–2672.
25. Lê LH, Chetty R, Moore MJ. Epidermal growth factor receptor expression in anal canal carcinoma. Am J Clin Pathol 2005;124: 20–23.
26. Ajani JA, Wang X, Izzo JG, Crane CH, Eng C et al. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci 2010;55: 1098–1105.
27. Leechanachai P, Banks L, Moreau F, Matlashewski G. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene 1992;7:19–25.
28. Pim D, Collins M, Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 1992;7:27–32.
29. Straight SW, Hinkle PM, Jewers RJ, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 1993;67:4521–4532.
30. Genther Williams SM, Disbrow GL, Schlegel R, Lee D, Threadgill DW et al. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res 2005;65:6534–6542.
31. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998;177:361–367.
32. Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W et al. Genomewide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res 2014;24:185–199.
33. Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using realtime polymerase chain reaction analysis. Cancer 2002;94:2199–2210.
34. Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 1999;59:6132–6136.
35. Middleton K, Peh W, Southern S, Griffin H, Sotlar K et al. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 2003;77:10186–10201.
36. Griffin H, Soneji Y, van Baars R, Arora R, Jenkins D et al. Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM. Mod Pathol 2015;28:977–993.
37. Pirisi L, Creek KE, Doniger J, Dipaolo JA. Continuous cell lines with altered growth and differentiation properties originate after transfection of human keratinocytes with human papillomavirus type 16 DNA. Carcinogenesis 1988;9:1573–1579.
38. Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 2010; 42:794–800.
39. Hu D, Zhou J, Wang F, Shi H, Li Y et al. HPV-16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo. Arch Gynecol Obstet 2015;292: 1345–1354.
40. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 2006;110:525–541.
41. Isaacson Wechsler E, Wang Q, Roberts I, Pagliarulo E, Jackson D et al. Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression. J Virol 2012;86: 6358–6364.
42. Walker F, Abramowitz L, Benabderrahmane D, Duval X, Descatoire V et al. Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. Hum Pathol 2009;40:1517–1527.
43. Alvarez G, Perry A, Tan BR, Wang HL. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol 2006;19: 942–949.
44. Zuo JH, Zhu W, Li MY, Li XH, Yi H et al. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem 2011;112:2508–2517.
45. Lu Z, Jiang G, Blume-Jensen P, Hunter T. Epidermal growth factor- induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 2001;21:4016–4031.
46. Zhen Y, Guanghui L, Xiefu Z. Knockdown of EGFR inhibits growth and invasion of gastric cancer cells. Cancer Gene Ther 2014;21: 491–497.
47. Hanning JE, Groves IJ, Pett MR, Coleman N. Depletion of polycistronic transcripts using short interfering RNAs: cDNA synthesis method affects levels of non-targeted genes determined by quantitative PCR. Virol J 2013;10:159.
48. Akerman GS, Tolleson WH, Brown KL, Zyzak LL, Mourateva E et al. Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes. Cancer Res 2001;61:3837–3843.
49. Sizemore N, Choo CK, Eckert RL, Rorke EA. Transcriptional regulation of the EGF receptor promoter by HPV16 and retinoic acid in human ectocervical epithelial cells. Exp Cell Res 1998;244:349–356.
50. Peto M, Tolle-Ersü I, Kreysch HG, Klock G. Epidermal growth factor induction of human papillomavirus type 16 E6/E7 MRNA in tumor cells involves two AP-1 binding sites in the viral enhancer. J Gen Virol 1995;76:1945–1958.
51. Rosenberger S, de-Castro Arce J, Langbein L, Steenbergen RD, Rösl F. Alternative splicing of human papillomavirus type-16 E6/ E6* early mRNA is coupled to EGF signaling via Erk1/2 activation. Proc Natl Acad Sci USA 2010;107:7006–7011.
52. Wheeler CM, Yamada T, Hildesheim A, Jenison SA. Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization. J Clin Microbiol 1997;35:11–19.
53. Lambert PF, Ozbun MA, Collins A, Holmgren S, Lee D et al. Using an immortalized cell line to study the HPV life cycle in organotypic “raft” cultures. Methods Mol Med 2005;119:141–155.